52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

PHASE3TerminatedINTERVENTIONAL
Enrollment

558

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Ibodutant 10 mg

Oral tablet, to be given once daily.

DRUG

Placebo

Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.

Trial Locations (139)

1002

Riga

1005

Riga

1006

Riga III

1088

Budapest

1136

Budapest

2600

Vác

4032

Debrecen

4043

Debrecen

4201

Valmiera

4700

Mátészalka

5417

Daugavpils

5703

Gyula

7100

Szekszárd

7624

Pécs

10016

New York

10117

Berlin

11023

Great Neck

11235

Brooklyn

12627

Berlin

14186

Stockholm

19055

Schwerin

19056

Levittown

21045

Columbia

22222

Lund

22297

Hamburg

24502

Lynchburgh

26126

Příbram

27103

Winston-Salem

27262

High Point

28100

Staszów

28144

Salisbury

28602

Hickory

29621

Anderson

30159

Hanover

33012

Hialeah

33014

Miami Lakes

33016

Hialeah

Miami Lakes

33135

Miami

33165

Miami

33173

Miami

33185

Miami

33186

Miami

33319

Lauderdale Lakes

Tamarac

33606

Tampa

33782

Pinellas Park

33916

Fort Myers

34452

Inverness

34741

Kissimmee

37001

České Budějovice

37660

Kingsport

38138

Germantown

38305

Jackson

40772

Katowice

41345

Gothenburg

44060

Mentor

44787

Bochum

45005

Franklin

45224

Cincinnati

47714

Evansville

49519

Wyoming

50012

Kralove

50325

Clive

50556

Wroclaw

54144

Wroclaw

55116

Mainz

59102

Billings

60101

Addison

60355

Poznan

60453

Oak Lawn

60596

Frankfurt

61107

Rockford

61606

Poznan

63128

St Louis

66218

Shawnee

70006

Metairie

71103

Shreveport

72117

North Little Rock

72211

Little Rock

72212

Little Rock

75185

Uppsala

76001

Zlín

76012

Arlington

76199

Karlsruhe

77074

Houston

78229

San Antonio

80112

Centennial

80906

Colorado Springs

81756

Sopot

82107

Bratislava

83104

Bratislava

84094

Sandy City

84341

Logan

84405

Ogden

85012

Phoenix

85101

Bratislava

85202

Mesa

85224

Chandler

85308

Glendale

90153

Lodz

91101

Trenčín

91105

Pasadena

91436

Encino

91606

North Hollywood

91701

Trnava

92108

San Diego

92653

Laguna Hills

92868

Orange

94901

Nitra

95648

Lincoln

95670

Gold River

98105

Seattle

99208

Spokane

02301

Brockton

02302

Brockton

03801

Newington

28501-1584

Kinston

500 02

Hradec Králové

130 00

Prague

274 51

Slaný

04103

Leipzig

H 1032

Budapest

01231

Warsaw

02018

Warsaw

02679

Warsaw

03580

Warsaw

01901

Ilava

TN40 1JJ

Bexhill-on-Sea

PR7 7NA

Chorley

CV2 2DX

Coventry

B15 2SQ

Edgbaston

G20 0SP

Glasgow

CF14 5GJ

Llanishen

M15 6SX

North Manchester

NE46 1QJ

Northumberland

NR4 7UY

Norwich

RG2 0TG

Reading

L22 0LG

Waterloo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Menarini Group

INDUSTRY

NCT02120027 - 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) | Biotech Hunter | Biotech Hunter